tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Fungemia D016469 2 associated lipids
Legionellosis D007876 3 associated lipids
Lung Abscess D008169 1 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Alopecia Areata D000506 6 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Polymyositis D017285 1 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Blepharitis D001762 4 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Erythema Nodosum D004893 5 associated lipids
Sweet Syndrome D016463 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Deglutition Disorders D003680 2 associated lipids
Oral Ulcer D019226 1 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Epididymitis D004823 1 associated lipids
Orchitis D009920 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Citrullinemia D020159 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Hand Injuries D006230 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Pemphigus D010392 3 associated lipids
Mutism D009155 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Intestinal Atresia D007409 3 associated lipids
Priapism D011317 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Trichomonas Infections D014245 3 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
West Nile Fever D014901 1 associated lipids
Foot Ulcer D016523 4 associated lipids
Fibroadenoma D018226 2 associated lipids
Tinea Capitis D014006 1 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Lymphocele D008210 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Angiofibroma D018322 2 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Cheilitis D002613 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Optic Neuritis D009902 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Balanitis D001446 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gołębiewska J et al. Tako-tsubo cardiomyopathy on the first day after renal transplantation - case report and literature review. 2014 Transplant. Proc. pmid:25380951
Candinas D et al. Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. 1994 Transplant. Proc. pmid:7527959
Yuan QS et al. Rescue therapy with tacrolimus in renal graft patients with cyclosporine A-induced hepatotoxicity: a preliminary study. 2000 Transplant. Proc. pmid:11119896
Alessiani M et al. Adverse effects of FK 506 overdosage after liver transplantation. 1993 Transplant. Proc. pmid:7679825
Nishikawa K et al. Experimental studies of vascularized joint allografts in rats. 1994 Transplant. Proc. pmid:7513482
Kobayashi M et al. FK 506 assay past and present--characteristics of FK 506 ELISA. 1991 Transplant. Proc. pmid:1721258
TuÄŸcu M et al. Tacrolimus-Induced Diabetic Ketoacidosis and Effect of Switching to Everolimus: A Case Report. 2015 Transplant. Proc. pmid:26093759
Bechstein WO et al. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. 1996 Transplant. Proc. pmid:8623211
Aktürk S et al. Pregnancy After Kidney Transplantation: Outcomes, Tacrolimus Doses, and Trough Levels. 2015 Transplant. Proc. pmid:26093738
Shoji T et al. Long-term acceptance of porcine pulmonary allografts without chronic rejection. 2005 Jan-Feb Transplant. Proc. pmid:15808551
Mieles L et al. Oral glucose tolerance test in liver recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689894
Asensio M et al. Experience with tacrolimus as primary immunosuppressor in pediatric liver transplant. 2002 Transplant. Proc. pmid:11959208
Millis JM et al. Successful use of tacrolimus for initial rejection episodes after liver transplantation. 1998 Transplant. Proc. pmid:9636569
Qu W et al. Correlation Between Immunosuppressive Therapy and CD4(+) T-Cell Intracellular Adenosine Triphosphate Levels in Liver Transplant Recipients. Transplant. Proc. pmid:27569951
Martín-Mateos RM et al. Initial immunosuppression with or without basiliximab: a comparative study. 2012 Transplant. Proc. pmid:23146457
Fukuzaki T et al. Induction of unresponsiveness to islet allograft by preoperative donor spleen cell injection and FK 506 treatment. 1993 Transplant. Proc. pmid:7680173
Oishi M et al. A case of hyperkalemic distal renal tubular acidosis secondary to tacrolimus in living donor liver transplantation. 2000 Transplant. Proc. pmid:11120143
Nakamuta M et al. Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. 2005 Transplant. Proc. pmid:16387179
Kim HC et al. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. 2004 Transplant. Proc. pmid:15518753
Loréal O et al. FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. 1991 Transplant. Proc. pmid:1721289
Matsuzaki T et al. Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats. 1992 Transplant. Proc. pmid:1373547
Soriano S et al. Single-center experience with initial intravenous dosing of tacrolimus after kidney transplantation. 1999 Transplant. Proc. pmid:10576045
McCauley J et al. Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. 1991 Transplant. Proc. pmid:1721290
Pirenne J et al. Bone marrow augmentation of kidney allografts can cause graft-versus-host disease in immunosuppressed recipients. 1996 Transplant. Proc. pmid:8623472
Ciancio G et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. 1996 Transplant. Proc. pmid:8623473
Thomas FT et al. Comparative efficacy of immunosuppressive drugs in xenografting. 1990 Transplant. Proc. pmid:1693452
Comuzzi C et al. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. 2010 Transplant. Proc. pmid:20534291
Stratta RJ Late acute rejection episodes after vascularized pancreas transplantation. 1998 Transplant. Proc. pmid:9636633
Marchewka Z et al. Kidney graft function in long-term cyclosporine and tacrolimus treatment: comparative study with nephrotoxicity markers. 2009 Transplant. Proc. pmid:19545703
Herrero MJ et al. Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation. 2010 Transplant. Proc. pmid:20970643
Platz KP et al. Indications for mycofenolate mofetil therapy after liver transplantation. 1997 Transplant. Proc. pmid:9365601
Lischke R et al. Initial single-center experience with sirolimus after lung transplantation. 2006 Transplant. Proc. pmid:17112886
Demirbas A et al. FK 506 in simultaneous pancreas/kidney transplantation: the University of Miami experience. 1997 Transplant. Proc. pmid:9365608
Curro G et al. Transient ischemic attack after rizatriptan administration in a liver transplant recipient: a case report. 2006 Transplant. Proc. pmid:17112920
Reyes J et al. Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression. 1994 Transplant. Proc. pmid:7518137
Falkiewicz K et al. Tacrolimus decreases tubular phosphate wasting in renal allograft recipients. 2003 Transplant. Proc. pmid:14529892
Ziolkowski J et al. Effect of immunosuppressive regimen on acute rejection and liver graft function. 2003 Transplant. Proc. pmid:14529915
Meiser BM et al. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. 1993 Transplant. Proc. pmid:7682363
O'Rourke M et al. Recovery of delayed-type hypersensitivity following liver transplantation. 1995 Transplant. Proc. pmid:7533369
Kato T et al. FK506 may suppress liver injury during the early period following living-related liver transplantation. 2003 Transplant. Proc. pmid:12591316
Fukuzawa M et al. Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. 1991 Transplant. Proc. pmid:1721321
Moreno Gonzales M et al. Sublingual Tacrolimus in Liver Transplantation: A Valid Option? Transplant. Proc. pmid:27569953
Ennaifer R et al. Nodular hyperplasia of the gastrointestinal tract after liver transplantation: role of immunosuppressive therapy? A case report. 2015 Transplant. Proc. pmid:25891739
Benedini S et al. Glucose and leucine metabolism in lung tranplanted patients on low dose of steroids for immunosuppressive therapy. 2008 Transplant. Proc. pmid:18589153
Stockmann M et al. Influence of immunosuppressive drugs on intestinal epithelial transport function. 2002 Transplant. Proc. pmid:12176434
Waller JR et al. Effect of rapamycin in combination with calcineurin inhibitors, FK506 and cyclosporin, following arterial injury. 2002 Transplant. Proc. pmid:12176449
Wasiak D et al. Delayed, Uncommon Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Case Report. 2016 Transplant. Proc. pmid:27496507
Numakura K et al. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients. 2005 Transplant. Proc. pmid:15919487
Izutani H et al. Graft coronary arteriosclerosis in rat heart transplant model with FK 506 short-term administration. 1995 Transplant. Proc. pmid:7533425
Funayama Y et al. Changes in cell adhesion molecules after small bowel transplantation in rats. 1995 Transplant. Proc. pmid:7533426
Colak T et al. Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients. 2002 Transplant. Proc. pmid:12270321
Paul AA et al. CMV retinitis and the use of FK 506. 1991 Transplant. Proc. pmid:1721354
Waller JR et al. Primary immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared with neoral therapy. 2002 Transplant. Proc. pmid:12176496
De Ruvo N et al. Preliminary results of immunosuppression with thymoglobuline pretreatment and hepatitis C virus recurrence in liver transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182760
Gruttadauria S et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182762
Sasaki K et al. Effect of FK 506 and splenectomy on orthotopic small bowel xenotransplantation in the hamster-to-rat animal models. 1998 Transplant. Proc. pmid:9838521
Marino IR et al. Preoperative assessment of risk in liver transplantation: a multivariate analysis in 2376 cases of the UW era. 1997 Feb-Mar Transplant. Proc. pmid:9123079
Alessiani M et al. Intestinal transplantation with and without the colon in FK 506 immunosuppressed pigs. 1996 Transplant. Proc. pmid:8908021
Nozaki S et al. Effect of brequinar sodium on accelerated cardiac allograft rejection in presensitized recipients. 1994 Transplant. Proc. pmid:7520633
Goller AL et al. Loss of serum bicarbonate after discordant liver xenotransplantation. 2000 Transplant. Proc. pmid:10936383
Endoh M et al. Nonmuscle myosin heavy chain and metalloproteinase-2 expression in concordant pulmonary xenografts. 2000 Transplant. Proc. pmid:10936397
Morris RE et al. Immunopharmacology of FK-506. 1989 Transplant. Proc. pmid:2468201
Tauxe WN et al. A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. 1991 Transplant. Proc. pmid:1721386
Yoshimura N et al. A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. 1989 Transplant. Proc. pmid:2468202
McCauley J et al. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. 1991 Transplant. Proc. pmid:1721387
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplant. Proc. pmid:12176542
Citterio F et al. Steroid withdrawal from tacrolimus-based therapy in renal transplant patients. 2002 Transplant. Proc. pmid:12176545
Hsu KH et al. Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience. 2010 Transplant. Proc. pmid:20430208
Steinmueller T et al. The effect of cyclosporine vs FK 506 on glucose metabolism. 1999 Feb-Mar Transplant. Proc. pmid:10083504
Iacona I et al. Mycophenolic acid in combination with FK 506: a pharmacokinetic study in piglets after small-bowel transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123489
Tatekawa Y et al. Intragraft expression of p38 in rat small bowel transplantation. 2000 Transplant. Proc. pmid:10995948
Karamperis N et al. Comparison of the pharmacokinetics of tacrolimus and cyclosporine at equivalent molecular doses. 2003 Transplant. Proc. pmid:12826146
Tzakis AG et al. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. 1991 Transplant. Proc. pmid:1721416
Tojimbara T et al. Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro. 1996 Transplant. Proc. pmid:8658704
Chang HR et al. Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity. 2004 Transplant. Proc. pmid:15621119
Land W et al. Tacrolimus versus cyclosporine in primary simultaneous pancreas-kidney transplantation: preliminary results at 1 year of a large multicenter trial. 2002 Transplant. Proc. pmid:12176625
Burke GW et al. Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen. 2002 Transplant. Proc. pmid:12176628
Lorenzini S et al. Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases. 2006 Transplant. Proc. pmid:16797338
Zamauskaite A et al. FK506 and CsA differ in their effect on intracellular cytokine expression following kidney transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267184
Aguirrezabalaga J et al. Lipid profiles in liver transplantation in patients receiving tacrolimus or cyclosporin. 2001 Feb-Mar Transplant. Proc. pmid:11267192
Donadio C et al. Tubular damage and impairment of renal function in transplanted kidneys. 1998 Transplant. Proc. pmid:9723381
Varghese Z et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. 1998 Transplant. Proc. pmid:9723384
Duzova A et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. 2003 Transplant. Proc. pmid:14697926
Davies CB et al. Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. 1991 Transplant. Proc. pmid:1721448
Reichenspurner H et al. First experience with FK 506 for treatment of chronic pulmonary rejection. 1995 Transplant. Proc. pmid:7540775
Abu-Elmagd K et al. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. 1991 Transplant. Proc. pmid:1721449
Dé P et al. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3? 1993 Transplant. Proc. pmid:7689279
Ueda D et al. Influence of FK 506 on renal blood flow. 1993 Transplant. Proc. pmid:7689280
Aidong W et al. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. 2004 Transplant. Proc. pmid:15561258
Sigal NH et al. Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. 1991 Transplant. Proc. pmid:1712132
Banerjee R et al. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267435
Isobe M et al. Downregulation of endothelin expression in allograft coronary arteries after gene therapy targeting Cdk2 kinase. 1998 Transplant. Proc. pmid:9636407
Ciancio G et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. 2010 Transplant. Proc. pmid:21094804
Kacar S et al. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. 2010 Transplant. Proc. pmid:21094806
Malinowski K et al. Effect of different anti-rejection regimens on the expression of differentiation and activation markers on the surface of host lymphocytes. 2000 Transplant. Proc. pmid:10856579
McLaughlin GE et al. Effect of aminophylline on urine flow in children with tacrolimus-induced renal insufficiency. 2000 Transplant. Proc. pmid:10856596
Jørgensen KA et al. Optimal time for determination of blood tacrolimus level. 2001 Nov-Dec Transplant. Proc. pmid:11750358
Ott R et al. Conversion from tacrolimus to Neoral in liver and kidney transplant recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750359
Loss GE et al. Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. 1998 Transplant. Proc. pmid:9636508
Kliem V et al. Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients. 1998 Transplant. Proc. pmid:9636509